CRA II - SCRA I - Midlands - FSP
Fortrea
MaidenheadPosted 2 days agoDiscoveredMatch locked
Full time2+ years exp
About the role
Are you looking to grow your career in clinical research? Fortrea is hiring a
CRA II/SCRA
to join our dynamic FSP team. We have opportunities across the UK, particularly in the
Midlands
, offering an exciting chance to work on diverse studies while ensuring compliance with regulatory guidelines and company SOPs.
Why Join Fortrea?
- Be part of a
global, innovative organization
driving advancements in clinical research.
- Work on cutting-edge trials across a range of therapeutic areas.
- Enjoy
flexible career progression
, with opportunities at different CRA levels.
- Benefit from a
collaborative team environment
that values mentorship and growth.
Key Responsibilities:
- Conduct and oversee study site monitoring visits to ensure compliance with protocols and regulatory requirements.
- Manage all aspects of site activities, including
site initiation, monitoring visits and closeouts
.
- Ensure patient safety, data integrity, and adherence to
GCP
guidelines.
- Support feasibility assessments, investigator recruitment and vendor coordination.
- Mentor junior team members and contribute to quality control efforts.
- Track and report
Serious Adverse Events (SAEs)
as required.
Qualifications:
- University/college degree in life sciences or a relevant allied health field.
- At least
2 years of experience
in a related role (e.g., Site Management, CRA).
- Basic knowledge of
Regulatory Guidelines and the clinical trial process
.
- Strong communication, organizational, and problem-solving skills.
- A
valid driver’s license
and willingness to travel.
Learn more about our EEO & Accommodations request here .
Skills
gcp
Who can apply
The employer didn't state any visa, work authorization, citizenship or clearance requirements in this posting. Confirm with the employer before applying.
Read automatically from the employer's posting text. Always confirm with the employer — requirements can change after a job is published.